Canada

Health Canada is the federal department responsible for regulating health products in Canada, operating under the authority of the Food and Drugs Act (FDA) and its associated regulations, including the Medical Devices Regulations (SOR/98-282) and the Food and Drug Regulations (C.R.C., c. 870). Health Canada's Health Products and Food Branch (HPFB) oversees the review and authorization of pharmaceuticals, biologics, medical devices, in vitro diagnostics, and digital health technologies. All health products must receive a market authorization, such as a Drug Identification Number (DIN), a Natural Product Number (NPN), or a Medical Device Licence (MDL), before they can be legally sold in Canada. Devices are classified into four risk-based classes (Class I through Class IV), with regulatory requirements escalating accordingly.

Canada accepts submissions prepared according to the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for pharmaceuticals and biologics, aligning closely with international standards. Foreign manufacturers are required to designate a Canadian Importer or Regulatory Correspondent responsible for correspondence with Health Canada. Recent reforms include the introduction of the Interim Order and Agile Licensing frameworks, which were accelerated during the COVID-19 pandemic to enable faster authorization of urgent health products. Health Canada has also advanced its Digital Health Technology guidance and participates in collaborative work-sharing initiatives such as ORBIS (with the FDA and other regulators) and the Access Consortium (with Australia, Singapore, Switzerland, and the United Kingdom), allowing parallel scientific reviews to reduce duplication and approval timelines for sponsors.

Canada operates a federated procurement model in which responsibility for health product purchasing is shared between the federal government and thirteen provincial and territorial governments. Each province and territory administers its own public drug plan and healthcare system, funded through a combination of federal transfers and provincial revenues. The federal government, through Public Services and Procurement Canada (PSPC) and the Public Health Agency of Canada (PHAC), manages procurement for federal populations such as Indigenous communities, military personnel, and federal inmates. Pan-Canadian collaborative purchasing is coordinated through the pan-Canadian Pharmaceutical Alliance (pCPA), which conducts joint price negotiations for publicly funded drugs on behalf of participating provinces, territories, and federal programs. Hospitals and regional health authorities typically procure medical devices and diagnostics through group purchasing organizations (GPOs) such as HealthPRO and the Canadian Collaborative Procurement Initiative (CCPI), which leverage collective volume to negotiate pricing.

The private sector plays a significant role in Canada, with employer-sponsored and individual private insurance plans covering a substantial portion of pharmaceutical and device expenditures outside of public formularies. Canada does not typically rely on multilateral donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, or USAID, as it is a high-income donor country rather than a recipient of such programs. However, Canadian institutions, including the Public Health Agency of Canada and Global Affairs Canada, contribute funding and health commodities to global health initiatives internationally. Canada has historically had limited explicit local manufacturing preference policies for health product procurement, though the COVID-19 pandemic catalyzed a renewed federal focus on domestic biomanufacturing capacity through the Biomanufacturing and Life Sciences Strategy, launched in 2021, which aims to reduce supply chain vulnerability and incentivize domestic production of vaccines, biologics, and other critical health products.